Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Fulcrum Therapeutics is a biotechnology business based in the US. Fulcrum Therapeutics shares (FULC) are listed on the NASDAQ and all prices are listed in US Dollars. Fulcrum Therapeutics employs 89 staff and has a trailing 12-month revenue of around $6.3 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $3.14 |
|---|---|
| 52-week range | $3.07 - $24.79 |
| 50-day moving average | $9.60 |
| 200-day moving average | $7.49 |
| Wall St. target price | $9.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.22 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.14 from 2023-03-29
| 1 week (2023-03-24) | -0.32% |
|---|---|
| 1 month (2023-03-03) | -47.58% |
| 3 months (2022-12-30) | -56.87% |
| 6 months (2022-09-30) | -61.19% |
| 1 year (2022-03-28) | -84.69% |
|---|---|
| 2 years (2021-03-31) | -73.34% |
| 3 years (2020-03-31) | 11.94 |
| 5 years (2018-03-27) | N/A |
| Revenue TTM | $6.3 million |
|---|---|
| Gross profit TTM | $-70,440,000 |
| Return on assets TTM | -30.36% |
| Return on equity TTM | -53.53% |
| Profit margin | 0% |
| Book value | $3.82 |
| Market capitalisation | $203.6 million |
TTM: trailing 12 months
We're not expecting Fulcrum Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Fulcrum Therapeutics's shares have ranged in value from as little as $3.065 up to $24.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulcrum Therapeutics's is 2.2459. This would suggest that Fulcrum Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.